WADA Prohibited List raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-07. Anything still debated is marked as such rather than presented as settled.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Plasmin is a serine protease that acts to dissolve fibrin blood clots. Apart from fibrinolysis, plasmin proteolyses proteins in various other systems: It activates collagenases, some mediators of the complement system, and weakens the wall of the Graafian follicle, leading to ovulation. Plasmin is also integrally involved in inflammation. It cleaves fibrin, fibronectin, thrombospondin, laminin, and von Willebrand factor. Plasmin, like trypsin, belongs to the family of serine proteases. Plasmin is released as a zymogen called plasminogen (PLG) from the liver into the systemic circulation. Two major glycoforms of plasminogen are present in humans - type I plasminogen contains two glycosylation moieties (N-linked to N289 and O-linked to T346), whereas type II plasminogen contains only a single O-linked sugar (O-linked to T346). Type II plasminogen is preferentially recruited to the cell surface over the type I glycoform. Conversely, type I plasminogen appears more readily recruited to blood clots. In circulation, plasminogen adopts a closed, activation-resistant conformation. Upon binding to clots, or to the cell surface, plasminogen adopts an open form that can be converted into active plasmin by a variety of enzymes, including tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), kallikrein, and factor XII (Hageman factor). Fibrin is a cofactor for plasminogen activation by tissue plasminogen activator. Urokinase plasminogen activator receptor (uPAR) is a cofactor for plasminogen activation by urokinase plasminogen activator.
Electroanalytical methods measure the potential (volts) and/or current (amps) in an electrochemical cell containing the analyte. These methods can be categorized according to which aspects of the cell are controlled and which are measured. The four main categories are potentiometry (the difference in electrode potentials is measured), coulometry (the transferred charge is measured over time), amperometry (the cell's current is measured over time), and voltammetry (the cell's current is measured while actively altering the cell's potential).
=== Leaves === The leaf outline is mostly ovate to rhomboid. The outline can sometimes be elliptic or obovate. The leaf margin is dentate or deeply lobed. The indumentum of the leaves can vary. There is often a hairy upper surface, and the lower surface can be sparsely to densely hairy. It has been described as feeling velvety. When the leaves are crushed, there is an unpleasant scent. This may be due to the pelate hairs or pelate glands on the leaves. The leaves are opposite whorls of 3–4. The petiole is 0–24 mm long.
=== Genetics === PMOS has a clear genetic component and high heritability. Evidence of the genetic basis comes from family and twin studies, as well as from large genome-wide association studies. The correlation in PMOS occurrence between identical twin sisters was found to be twice as high as that between non-identical twins, suggesting a significant genetic influence. Twenty-five different genetic loci have been found to correlate with PMOS in genome-wide association studies, of which thirteen were replicated in at least one other study. Variants in genes involved in insulin signaling and androgen synthesis, including those affecting ovarian steroidogenesis, have also been associated with increased susceptibility to PMOS. Genes near some of these loci imply neuroendocrine and metabolic dysfunction, but the role of other genes is not yet clear. Men with a family history of PMOS also display some of the symptoms associated with it. For instance, brothers of women with PMOS show a higher likelihood of high AMH levels, insulin resistance, and abnormal lipid levels in the blood. Men with the genetic risk factors associated with PMOS also have higher levels of obesity, type-2 diabetes, male pattern hair loss, and cardiovascular disease. Not all similarities between family members are likely due to genetics, as PMOS and obesity in mothers can have an impact on fetal development, making it more likely for men to get metabolic disorders with age.
While working at St Mary's Hospital, London in 1928, Alexander Fleming, a Scottish physician, was investigating the variation of growth in cultures of S. aureus, trying to replicate research from Trinity College Dublin. He spent the summer break with his family at his country home The Dhoon at Barton Mills, Suffolk. Before leaving his laboratory at the end of July, he inoculated several culture plates with S. aureus. He kept the plates aside on one corner of the table away from direct sunlight and to make space for his research student, Stuart Craddock, to work in his absence. He returned to his laboratory on 3 September. As he and Daniel Merlin Pryce, his former research student, examined the culture plates, they found one with an open lid and the culture contaminated with a blue-green mould. In the contaminated plate the bacteria around the mould did not grow, while those farther away grew normally, meaning that the mould killed the bacteria. Fleming photographed the culture and took a sample of the mould for identification. Fleming resumed his vacation and returned to St Mary's that month. He collected the original mould and grew it in culture plates. After four days he found that the plates developed large colonies of the mould. He repeated the experiment with the same bacteria-killing results. He concluded that the mould was releasing a substance that was inhibiting bacterial growth. On testing against different bacteria, he found that the mould could kill only certain Gram-positive bacteria.
Sources: en.wikipedia.org
== Veterinary uses == Although its use in veterinary medicine is highly restricted, chloramphenicol still has some important veterinary uses. It is currently considered the most useful treatment of chlamydial disease in koalas. The pharmacokinetics of chloramphenicol have been investigated in koalas.
national school-related group) SADL (a) Situation Awareness Data Link ("saddle") Structural Architecture Description Language SADT - (i) Substance Abuse Day Treatment SAE (i) Society of Automotive Engineers Stamped addressed envelope SAFER – (a) Steel And Foam Energy Reduction SAFETY – (a) Stopping Adults Facilitating the Exploitation of Today's Youth SAFICT – (a) Software Agents as Facilitators of Interoperability in Collective Training sag – (s) Sango language (ISO 639-2 code) SAG (a/i) Screen Actors Guild Surface Action Group SAG-AFTRA – (a) Screen Actors Guild–American Federation of Television and Radio Artists SAGAT – (a) Situation Awareness Global Assessment Technique SAGE – (a) Semi-Automatic Ground Environment (simulation) SAHB – (a) Sensational Alex Harvey Band SAIC – (i) Science Applications International Corporation SALT (a/i) Save A Life Today (SALT) Alert; Emergency Contact System (a) Southern African Large Telescope Strategic Arms Limitation Talks SAM (a) Sequential-Access Memory Sociedad Aeronáutica de Medellín Surface-to-Air Missile Sambo – (p/a) Samooborona bez oruzhiya (Russian: "Самооборона без оружия", literally "self-defense without weapons") SAML – (a) Security Assertion Markup Language ("sam-ell") SANZAAR – (a) South Africa, New Zealand, Australia and Argentina Rugby san (s) Sanskrit language (ISO 639-2 code) (a) Storage Area Network SAO - (more than 20 alternatives) SAR (s) Saudi riyal (ISO 4217 currency code) (a) Search And Rescue Special Administrative Region Synthetic Aperture Radar SARA (a) Southeastern Association for Research in Astronomy Scientific Atlanta Resident Application Scottish Amateur Rowing Association Southern African Railway Association State Administration for Religious Affairs SARP – (a) Search And Rescue Processor SARR – (i/a) Search And Rescue Repeater SARS – (a) Severe Acute Respiratory Syndrome SART (a) Search and Rescue Transponder Situational Awareness Rating Technique SARU – (i) South African Rugby Union SAS (i) Scandinavian Airlines System Second Avenue Subway Situational Awareness System Special Air Service Studies, Analysis and Simulation Side Angle Side (a) Statistical Analysis System (original meaning; SAS Institute Inc. has evolved far beyond that scope) SASE – (i) Self-Addressed Stamped Envelope SASO – (a) Stability and Support Operations SASOL – (p) Suid Afrikaanse Steenkool en Oli.e. (Afrikaans, "South African Coal and Oil") SAT (i) formerly Scholastic Aptitude Test and Scholastic Assessment Test; now known solely by the initials Small Arms Trainer SATB – (i) Soprano Alto Tenor bass SATNAV – (p) Satellite Navigation (Increasingly common GPS based system in new vehicles) SATs – (a) Standard Assessment Tasks and other similar terms describing tests used in English schools; see National Curriculum assessment#Terminology SAU – (s) Saudi Arabia (ISO 3166 trigram) SAVAK – (a) Sazamane Etelaat va Amniate Kechvar (Iranian "Security and Intelligence Service") SAW (i) ṣallā -llāhu ʿalayhī (wa-ʾālihī) wa-sallama (Arabic: صَلَّىٰ ٱللَّٰهُ عَلَيْهِ وَآلِهِ وَسَلَّمَ, "God bless him [and his family] and grant him peace"), an honorific suffix within Islam for Muhammad (a) Submerged arc welding Squad Automatic Weapon Surface acoustic wave SAWE – (a) Society of Allied Weight Engineers SAWS – (i) alternate form of the Islamic honorific suffix for Muhammad (see SAW)
However, the restrictive protocol is not an option with some especially vulnerable patients who may require the best possible efforts to rapidly restore tissue oxygenation. Although transfusions of platelets are far less numerous (relative to RBC), platelet storage lesion and resulting efficacy loss is also a concern.
CFTR mutations that are responsive to elexacaftor/tezacaftor/ivacaftor were determined by an in-vitro study of Fischer Rat Thyroid (FRT) cells that expressed mutant CFTR. Elexacaftor/tezacaftor/ivacaftor showed effectiveness with mutations where the CFTR protein was being successfully delivered to the cell surface.
1993/288) National Health Service Trusts (Originating Capital Debt) Order 1993 (S.I. 1993/289) Council Tax (Alteration of Lists and Appeals) Regulations 1993 (S.I. 1993/290) Non-Domestic Rating (Alteration of Lists and Appeals) Regulations 1993 (S.I. 1993/291) Valuation and Community Charge Tribunals (Amendment) Regulations 1993 (S.I. 1993/292) A65 Trunk Road (Manor Park Improvement) Order 1993 (S.I. 1993/293) A65 Trunk Road (Denton Bridge to Black Bull Farm) (De-Trunking) Order 1993 (S.I. 1993/294) Family Proceedings (Amendment) Rules 1993 (S.I. 1993/295) Lands Tribunal for Scotland (Amendment) (Fees) Rules 1993 (S.I. 1993/296) Scottish Land Court (Fees) Order 1993 (S.I. 1993/297) Lyon Court and Office Fees (Variation) Order 1993 (S.I. 1993/298)
Sources: en.wikipedia.org
==== Greece ==== The production of potassium alum from alunite is archaeologically attested on the island Lesbos. This site was abandoned in the 7th century but dates back at least to the 2nd century CE.
Mescaline has been isolated from numerous cactus species, including Echinopsis (Trichocereus), Gymnocalycium, Lophophora, Opuntia, Stenocereus, and Turbinicarpus species, among others. It occurs at the highest known concentrations in Lophophora williamsii (peyote), where it is highly variable but makes up 0.1 to 0.255% fresh weight and 0.9 to 6.3% of dry weight. Levels of mescaline are much lower in other Lophophora species. The compound also occurs in relatively high concentrations in various Echinopsis species, for instance Echinopsis pachanoi (San Pedro cactus), ranging from 0.02 to 0.12% fresh weight and 0.331 to 2.0% dry weight in this species. Mescaline occurs in only small or trace amounts in most other cactus species in which it has been detected.
== Products and services == Eurogentec has developed three interrelated business units, Life Science Research Products and Services, In Vitro Diagnostics Manufacturing Solutions, and GMP Biomanufacturing.
3-Hydroxyphencyclidine (3-HO-PCP) is a dissociative of the arylcyclohexylamine class derived from PCP. It has been sold online as a designer drug. 3-HO-PCP primarily acts as an NMDA antagonist. However, it also has strong activity at opioid receptors compared to related drugs, and has significant activity at the σ1 receptor.
Tifluadom is a benzodiazepine derivative with an unusual activity profile. Unlike most benzodiazepines, tifluadom has no activity at the GABAA receptor, but instead is a selective agonist for the κ-opioid receptor. It has potent analgesic and diuretic effects in animals, and also has sedative effects and stimulates appetite. While tifluadom has several effects which might have potential uses in medicine, such as analgesia and appetite stimulation, κ-opioid agonists tend to produce undesirable effects in humans such as dysphoria and hallucinations, and so these drugs tend to only be used in scientific research. Dysphoric effects are similar to those seen when using other κ-opioid receptor agonists like pentazocine and salvinorin A, and can be considered the opposite of morphine-induced euphoria. As such, kappa agonists are believed to have very limited abuse potential.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.